Press Release

Cleanascite™ Cited in Nanopore Detection of Anticancer Drug

MONMOUTH JUNCTION, NJ, November 24, 2025 — Biotech Support Group (BSG) reports on its proprietary lipid removal reagent, Cleanascite™, in a nanopore detection study of the anticancer drug, Actinomycin D. 

Researchers from the University of Missouri, published an article entitled “A Label-free Nanopore Biosensor for Rapid and Highly Sensitive Detection of Actinomycin in Human Serum”, utilizing Cleanascite™ as sample prep to remove deleterious matrix effects from human serum.

Actinomycin D (ActD), a potent anticancer drug, binds specifically to DNA at GpC-rich sites. Detecting trace levels of ActD in human serum, is crucial for clinical, environmental, and pharmaceutical applications. For this purpose,a label-free detection method using an engineered α hemolysin (α-HL) nanopore was developed. Yet, human serum contains components, such as lipoproteins, that can disrupt the fragile lipid bilayer used to support the nanopore and/or cause frequent and long-duration channel blockage. Therefore, direct analysis of human serum by biological nanopore is challenging.

To overcome this matrix effect, the samples were first treated with Cleanascite™. Upon treatment, the results demonstrate that the matrix components in serum do not significantly interfere with ActD detection holding promise for clinical applications. Finally, this DNA-based nanopore platform offers a powerful, label-free tool for drug screening and discovery. 

“Cleanascite™ is now commonly used in many serum applications to remove matrix effects and maintain the integrity of finely tuned instruments. This is one of many references that demonstrate its advantaged workflow as a simple yet cost-effective sample prep product to clear lipid factors from serum or plasma, without interfering with downstream analysis.” stated Dr. Swapan Roy, President and Founder of Biotech Support Group.

For additional product details, visit:
Cleanascite™ Lipid Removal Reagent

About Biotech Support Group LLC
Biotech Support Group develops innovative sample preparation technologies that address the emerging needs of proteomics, biomarker discovery, and personalized medicine. Flagship products include Cleanascite™ for lipid removal, AlbuVoid™ and AlbuSorb™ PLUS for serum protein depletion, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance, family specific, and targeted proteome enrichment. These products support translational research by simplifying workflows and improving sample quality for downstream analysis.

For Business Development Inquiries:
Matthew Kuruc
Phone: 732-274-2866
Email: [email protected]

Keywords: Cleanascite™, serum lipid depletion, biological nanopore, actinomycin D, DNA-drug interaction, label-free drug screening